Navigation Links
China Yongxin Pharmaceuticals Inc. Launches Electronic Diagnosis System in its Changchun Drugstores
Date:3/16/2009

CHANGCHUN, China and LOS ANGELES, March 16 /PRNewswire-Asia-FirstCall/ -- China Yongxin Pharmaceuticals, Inc. ("China Yongxin Pharmaceuticals" or "the Company") (OTC Bulletin Board: CYXN), a leading manufacturer, distributor and retailer of pharmaceuticals in Northeastern China, today announced that it has rolled out its Electronic Diagnosis System in all of the chain drugstores located in Changchun, Jilin.

In order to ensure safety of drug usage in China, patients have to provide prescriptions from licensed medical physicians to purchase drugs classified as prescription drugs. Yongxin recently launched an Electronic Diagnosis System to enable its customers to remotely receive medical diagnosis and conveniently purchase prescription drugs in its all chain drugstores located throughout the Changchun. This system is the first electronic diagnosis system of its kind to be launched in Jilin province. Pending success of the initial roll-out, the company's long-term plans include offering this diagnostic service to all of its existing and future drugstores.

The system connects stores with a centralized service center where licensed medical doctors provide diagnosis services to patients through an integrated, proprietary video and audio system. This service, which is offered to customers free of charge, enables them to immediately purchase drugs prescribed by the doctors in Yongxin's chain drugstores, instead of having to schedule an appointment with a physician beforehand and potentially going to a competing drugstore. The Electronic Diagnosis System can also reduce errors caused through traditional written prescriptions, improve efficiency and prevent fake prescriptions.

Yan Jiangyin, Spokesperson and Vice Chief of Politics & Law Department of China's State Food and Drug Administration, visited Yongxin and praised the launch of its Electronic Diagnosis System. Chinese Central TV, Chinese Medicine Newspaper a
'/>"/>

SOURCE China Yongxin Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. China Nepstar Chain Drugstore Announces Dividend
2. China Sky One Medical to Attend Two Conferences in March
3. China Sky One Medical, Inc. Obtains SFDA Approval for Policresulen Vaginal Suppositories
4. China Pharma Holdings, Inc. to Host Fourth Quarter 2008 Earnings Conference Call at 8:30 a.m. EDT Wednesday March 18, 2009
5. China Yingxia International, Inc.s chairwoman and CEO is in talks with investors in China
6. China Healthcare Acquisition Corp. Announces Stockholder Approval of Charter Amendment to Permit Early Distribution of Its Trust Fund and to Permit Its Continued Existence Without Blank Check Company Provisions and Sets Payment Date
7. Chindex International, Inc. to Participate in the Piper Jaffray & ChinaVenture Investment Conference 2009
8. China Shenghuo Announces Management Expansion and Enhanced Internal Controls
9. China Sky One Medical Inc. Gets SFDA Approval for Calcium Folinate Injection
10. China Nepstar Chain Drugstore to Announce Fourth Quarter and Fiscal 2008 Financial Results on March 16
11. University of the Rockies Faculty and Students Travel to China to Share Western Philosophy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...h., Dec. 3 Van Andel Research Inst... how the plant hormone abscisic acid (ABA) works a...vironmental stresses such as drought and cold. Th...ould help engineer crops that thrive in harsh envi...hortages. The findings could also have implicatio...
(Date:12/2/2009)...c. 2 Reportlinker.com announces th...s catalogue: ,, Sterilization Technologies: T...m/p0166820/Sterilization-Technologies-The-US-Marke...capital equipment to the sterilization industry in...growth rate for 2009-2014. ,, Explains how the ...
(Date:12/2/2009)...ec. 2 Reportlinker.com announces t...ts catalogue: ,, Kinase Inhibitors: Global Ma...19/Kinase-Inhibitors-Global-Markets.html ,, ...r the years 2005 through 2008, and projections for...s) through 2014 ,, An overview of the market f...
(Date:12/2/2009)... 2 In response to a pr...afety Now ," an initiative from the U.S. Anti-Do...ouncil for Responsible Nutrition (CRN), the leadin...ement industry, issued the following statement: ,... CEO: ,, "We share the concerns of Travis Tyg...
(Date:12/2/2009)...Korea, Dec. 2 The City ...com (KT), MacroEye and Qualcomm Incorporated (Nasd...tive, today announced the expansion of a project t...ions through the "Seoul Family Helper" program. T...o caregivers and senior citizens in order to provi...
Breaking Medicine News(10 mins):Health News:VAI Researchers Find Long Awaited Key to Creating Drought Resistant Crops 2Health News:VAI Researchers Find Long Awaited Key to Creating Drought Resistant Crops 3Health News:VAI Researchers Find Long Awaited Key to Creating Drought Resistant Crops 4Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 2Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 3Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 4Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 5Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 6Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 7Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 8Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 9Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 10Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 11Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 12Health News:Reportlinker Adds Sterilization Technologies: The U.S. Market 13Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 2Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 3Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 4Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 5Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 6Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 7Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 8Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 9Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 10Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 11Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 12Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 13Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 14Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 15Health News:CRN Responds to 'Supplement Safety Now' Initiative 2Health News:CRN Responds to 'Supplement Safety Now' Initiative 3Health News:Qualcomm, City of Seoul, Korea Telecom and MacroEye Leverage the Power of 3G to Connect Low Income and Disabled Senior Citizens to Caregivers 2Health News:Qualcomm, City of Seoul, Korea Telecom and MacroEye Leverage the Power of 3G to Connect Low Income and Disabled Senior Citizens to Caregivers 3Health News:Qualcomm, City of Seoul, Korea Telecom and MacroEye Leverage the Power of 3G to Connect Low Income and Disabled Senior Citizens to Caregivers 4
... September 6, PARI,Respiratory Equipment will be f...as part of their "Breathe Easier" series. PARI is ...at provides patients, such as COPD,sufferers, with...y respiratory,diseases and those who care for them...
... overweight or obese at age 45 , , FRIDAY,...erican adults will develop osteoarthritis of the k... obese in middle age, a new study says. , A perso...ill study. People who were of normal weight at age...
...on models are enhanced by taking into account risk...ity, according to research teams led by epidemiolo...ncer Center in two complementary papers appearing ... increased exposure to certain risks. Based upon t...
...ate Medicare Advantage (MA) plans will be paid an ...pared to what the same enrollee would have cost in... according to a new report from The Commonwealth F...ke effect beginning in 2010 had been fully in pla...
...nd pancreatic tumors , , THURSDAY, Sept. 4...scoveries involving genetic mutations of two deadl...creatic cancer -- may lead to new treatments and e...p of these deadly cancers," Kenneth Kinzler, a pro...
...rtin Schiff, M.D.,is an illustrious member and rec...nd weight loss. His career is detailed in "Who,s W... Who in America," "Who,s Who in,the World," "Who,s...theories and notions concerning weight control and...
Other Medicine News:Health News:PARI Respiratory Equipment Featured on Oxygen Network 2Health News:Almost Half of Adults Will Develop Knee Osteoarthritis by 85 2Health News:Creating lung cancer risk models for specific populations refines prediction 2Health News:Creating lung cancer risk models for specific populations refines prediction 3Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2Health News:Genetic Mutations Linked to Deadly Cancers 2Health News:Genetic Mutations Linked to Deadly Cancers 3Health News:Genetic Mutations Linked to Deadly Cancers 4Health News:Phone World-famed Martin Schiff, M.D., at 310-454-6172 for Free Weight Loss 'No Diet, No Stuff' Method. Hates Diets, Loves to Have People Help Themselves 2
(Date:12/2/2009)..., , NEW YORK, Dec. 2 /PRNewswire/ -...earch report is available in its catalogue: ,, ...Markets ,, http://www.reportlinker.com/p0166...-Markets.html ,, Offer a comprehensive view of...e basis ,, Provide an overview of the major typ...
(Date:12/2/2009)..., , FRAZER, Pa., Dec. 2 /PRNewswire-...y announced that it has filed a lawsuit in U.S. Di...als USA, Inc. for infringement of U.S. Patent Nos....46 Patent") and RE37,516 (the ",516 Patent") for t...blets [C-IV]. Cephalon has a three-year period of...
(Date:12/2/2009)..., , NEW YORK, Dec. 2 /PRNewswire/ ...search report is available in its catalogue: ,,...p; Market Trends ,, http://www.reportlinker.c...nology--Market-Trends.html ,, The fast develo...tnessing a flurry of activity with pharmaceutical ...
Breaking Medicine Technology:Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 2Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 3Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 4Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 5Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 6Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 7Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 8Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 9Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 10Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 11Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 12Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 3Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 4Reportlinker Adds Chiral Technology - International Technology & Market Trends 2Reportlinker Adds Chiral Technology - International Technology & Market Trends 3Reportlinker Adds Chiral Technology - International Technology & Market Trends 4Reportlinker Adds Chiral Technology - International Technology & Market Trends 5Affymetrix Reports Second Quarter 2009 Results 52465 1Affymetrix Reports Second Quarter 2009 Results 52465 2Affymetrix Reports Second Quarter 2009 Results 52465 3Affymetrix Reports Second Quarter 2009 Results 52465 4Affymetrix Reports Second Quarter 2009 Results 52465 5Affymetrix Reports Second Quarter 2009 Results 52465 6Affymetrix Reports Second Quarter 2009 Results 52465 7Affymetrix Reports Second Quarter 2009 Results 52465 8Human Genome Sciences Announces Second Quarter 2009 Financial Results and Key Developments 52463 1Human Genome Sciences Announces Second Quarter 2009 Financial Results and Key Developments 52463 2Human Genome Sciences Announces Second Quarter 2009 Financial Results and Key Developments 52463 3Human Genome Sciences Announces Second Quarter 2009 Financial Results and Key Developments 52463 4Human Genome Sciences Announces Second Quarter 2009 Financial Results and Key Developments 52463 5Human Genome Sciences Announces Second Quarter 2009 Financial Results and Key Developments 52463 6Human Genome Sciences Announces Second Quarter 2009 Financial Results and Key Developments 52463 7Human Genome Sciences Announces Second Quarter 2009 Financial Results and Key Developments 52463 8Human Genome Sciences Announces Second Quarter 2009 Financial Results and Key Developments 52463 9Human Genome Sciences Announces Second Quarter 2009 Financial Results and Key Developments 52463 10Human Genome Sciences Announces Second Quarter 2009 Financial Results and Key Developments 52463 11Human Genome Sciences Announces Second Quarter 2009 Financial Results and Key Developments 52463 12Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 1Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 2Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 3Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 4Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 5Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 6Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 7Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 8
...today reported one year,survival results from a Ph...on(R) (imexon for injection) in combination with d... or stage IV metastatic malignant,melanoma. Result...se I and,Phase II shows a 11.7 month overall mean ... overall mean survival in the subset of patients w...
...Inc., a privately-held,specialty pharmaceutical co...nical trials sponsored by its wholly owned subsidi...laRx(R) GENTAMICIN SURGICAL IMPLANT for,the preven...sing., GENTAMICIN SURGICAL IMPLANT is a fully bio...ted with the broad spectrum aminoglycoside,antibio...
Other Medicine Technology:AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 2AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 3AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma 4Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients 2Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients 3Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients 4
Beaver Blades
Dermatome
Model 1990 Dermatome
34670x Bagolini's Striated Lenses Pair
Medicine Products: